Search results

450 results

Sorted by Relevance . Sort by Date

  1. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

  2. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

  3. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

  4. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

  5. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

  6. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

  7. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

  8. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

  9. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.

  10. Mental wellbeing at work

    In development [GID-NG10140] Expected publication date: 15 December 2021

  11. Postnatal care

    In development [GID-NG10070] Expected publication date: 07 April 2021

  12. Acute coronary syndromes

    In development [GID-NG10085] Expected publication date: 18 November 2020

  13. Shared decision making

    In development [GID-NG10120] Expected publication date: 17 June 2021

  14. Antenatal care

    In development [GID-NG10096] Expected publication date: 11 August 2021

  15. Caesarean section (update)

    In development [GID-NG10081] Expected publication date: 31 March 2021

  16. Inducing labour (update)

    In development [GID-NG10082] Expected publication date: 14 October 2021

  17. Acne Vulgaris: Management

    In development [GID-NG10109] Expected publication date: 09 June 2021